Momenta Phama (MNTA) to Cease Further Enrollment in Necuparanib Phase 2 Per IDSMB Recommendation
Tweet Send to a Friend
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
